The estimated Net Worth of Robert F Byrnes is at least $260 Mille dollars as of 12 February 2016. Mr. Byrnes owns over 10,999 units of Revance Therapeutics Inc stock worth over $72,373 and over the last 11 years he sold RVNC stock worth over $0. In addition, he makes $187,947 as Independent Director at Revance Therapeutics Inc.
Sign up
Mr. Byrnes RVNC stock SEC Form 4 insiders trading
Robert has made over 3 trades of the Revance Therapeutics Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently he exercised 10,999 units of RVNC stock worth $44,216 on 12 February 2016.
The largest trade he's ever made was exercising 10,999 units of Revance Therapeutics Inc stock on 12 February 2016 worth over $44,216. On average, Robert trades about 1,897 units every 39 days since 2014. As of 12 February 2016 he still owns at least 10,999 units of Revance Therapeutics Inc stock.
You can see the complete history of Mr. Byrnes stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Robert Byrnes biography
Robert F. Byrnes serves as Independent Director of the Company. Mr. Byrnes has served as a director of our Company since August 2004. Mr. Byrnes has spent over forty years in the medical device and biotechnology industries. From October 1997 until October 2002, and from January 2005 to the present, Mr. Byrnes has served as the President and Chief Executive Officer of Roan Advisors, Inc., an advisory service for healthcare organizations. From November 2002 to January 2005, he served as the President and Chief Executive Officer of Thermage, Inc., a medical device company focused on non-invasive tissue tightening. Mr. Byrnes has also served as Chairman and Chief Executive Officer of Tokos Medical Corporation, a healthcare services company, President of Caremark, Inc., a home healthcare service company, and Vice President of Marketing and Business Development for Genentech, Inc., a biotechnology company. He currently serves on the board of directors of Allego Ophthalmics, LLC. Mr. Byrnes holds a B.S. in Pharmacy from Ferris State University and an M.B.A. degree in Marketing and Finance from Loyola University, Chicago. Our board of directors believes that Mr. Byrnes’s operating experience in the medical device and biotechnology industries, combined with his prior board positions, make him qualified to serve on our board of directors.
What is the salary of Robert Byrnes?
As the Independent Director of Revance Therapeutics Inc, the total compensation of Robert Byrnes at Revance Therapeutics Inc is $187,947. There are 11 executives at Revance Therapeutics Inc getting paid more, with Mark Foley having the highest compensation of $17,190,400.
How old is Robert Byrnes?
Robert Byrnes is 75, he's been the Independent Director of Revance Therapeutics Inc since 2004. There are no older and 15 younger executives at Revance Therapeutics Inc.
What's Robert Byrnes's mailing address?
Robert's mailing address filed with the SEC is C/O REVANCE THERAPEUTICS, INC., 7555 GATEWAY BOULEVARD, NEWARK, CA, 94560.
Insiders trading at Revance Therapeutics Inc
Over the last 11 years, insiders at Revance Therapeutics Inc have traded over $29,070,398 worth of Revance Therapeutics Inc stock and bought 136,530 units worth $2,014,047 . The most active insiders traders include Vlad Coric, Julian S Gangolli e Angus C. Russell. On average, Revance Therapeutics Inc executives and independent directors trade stock every 31 days with the average trade being worth of $83,132. The most recent stock trade was executed by Erica Jordan on 16 April 2024, trading 2,392 units of RVNC stock currently worth $9,090.
What does Revance Therapeutics Inc do?
revance therapeutics, inc. is a specialty biopharmaceutical company focused on the development, manufacturing and commercialization of novel botulinum toxin products for multiple aesthetic and therapeutic indications. the company is leveraging its proprietary portfolio of botulinum toxin compounds combined with its patented transmts® peptide delivery system to address unmet needs in the $3 billion neurotoxin market. revance's proprietary transmts technology enables delivery of botulinum toxin a through two novel dose formulations, a needle-free topical form and an injectable form that may localize the drug to the site of injection resulting in a more targeted and potentially longer lasting delivery. revance is currently pursuing clinical development for two product candidates, topical rt001 and injectable rt002, in a broad spectrum of aesthetic and therapeutic indications. rt001 is a topical gel, which has the potential to be the first commercially available non-injectable dose form
What does Revance Therapeutics Inc's logo look like?
Complete history of Mr. Byrnes stock trades at Revance Therapeutics Inc
Revance Therapeutics Inc executives and stock owners
Revance Therapeutics Inc executives and other stock owners filed with the SEC include:
-
Mark Foley,
President, Chief Executive Officer, Director -
Abhay Joshi,
Chief Operating Officer, President - R&D and Product Operations -
Tobin Schilke,
Chief Financial Officer -
Mark J. Foley,
CEO & Director -
Dustin Sjuts,
Chief Commercial Officer, Aesthetics & Therapeutics -
Dr. Abhay Joshi,
COO, Pres of R&D and Product Operations -
Dustin S. Sjuts,
Pres -
Tobin C. Schilke,
CFO & Principal Accounting Officer -
Chris Nolet,
Independent Director -
Jill Beraud,
Independent Director -
Angus Russell,
Independent Chairman of the Board -
Robert Byrnes,
Independent Director -
Philip Vickers,
Independent Director -
Phyllis Gardner,
Independent Director -
Julian Gangolli,
Independent Director -
Jeanie Herbert,
Sr. Director, Investor Relations -
Aubrey Rankin,
Director -
Dwight Moxie,
Senior Vice President, General Counsel, Corporate Secretary -
Azita Nejad,
Sr. VP of Technical Operations -
Justin Ford,
Sr. VP of HR & Head of People -
Taryn Conway,
VP of Marketing -
Jessica Serra,
Head of Investor Relations & ESG -
L Daniel Browne,
CEO and President -
James Walter Glasheen,
Director -
Ronald W Eastman,
Director -
Mark A Sr Prygocki,
Director -
Todd Erik Zavodnick,
CCO & President, -
Cyril Allouche,
Principal Accounting Officer -
Caryn Gordon Mc Dowell,
SVP, GC & Secretary -
Jacob Waugh,
Chief Scientific Officer -
Jonathan Tunnicliffe,
Director -
Ronald J Wooten,
Director -
Woodlands Health Ventures F...,
-
Arthur Peter Bertolino,
EVP and Chief Medical Officer -
Pharma Opportunities Fund I...,
-
Lauren P Silvernail,
CFO, Secretary & EVP Corp Dev. -
Curtis Ruegg,
EVP, Technical Operations -
Olivia C Ware,
Director -
Carey O Connor Kolaja,
Director -
Erica Jordan,
Chief Commercial Officer -
Vlad Coric,
Director